Repligen Corporation
Repligen Corporation (RGEN) Stock Ownership
Institutional vs insider vs public ownership from 13F and float data — top holders, activity, and insider trades below.
SEC 13F · FMP · RGEN · as of Sep 30, 2024
Ownership Breakdown
462
Institutional Holders
▼ 7 vs Q2
$8.25B
Total Inst. Value
▲ $1.18B vs Q2
56.41M
Shares Outstanding
freeFloat 94.60%
55.50M
13F Shares Held
▼ 576,094 vs Q2
Institutional ownership = 13F shares ÷ total outstanding. Insider % = 100 − free float. Public % = free float − institution %. Data: FMP /symbol-positions-summary + /shares-float + SEC EDGAR.
Top Institutional Holders
RGEN largest shareholders · institutional ownership
Q3 2024 · SEC 13F
Showing top 10 holders
| Holder | Shares | % Owned | Weight | Value | Reported | Change |
|---|---|---|---|---|---|---|
BLACKROCK, INC. biological products, (no diagnostic substances) | 7.11M | 12.69% | 12.69% | $1.06T | Nov 13, 2024 | NEW |
PRICE T ROWE ASSOCIATES INC /MD/ biological products, (no diagnostic substances) | 6.39M | 11.41% | 11.41% | $951.29B | Nov 14, 2024 | ▲ 1.78M |
VANGUARD GROUP INC biological products, (no diagnostic substances) | 5.04M | 9.01% | 9.01% | $750.70B | Nov 13, 2024 | ▼ 22.0K |
STATE STREET CORP biological products, (no diagnostic substances) | 1.62M | 2.90% | 2.90% | $241.64B | Nov 14, 2024 | ▼ 113.7K |
CHAMPLAIN INVESTMENT PARTNERS, LLC biological products, (no diagnostic substances) | 1.42M | 2.54% | 2.54% | $211.46B | Nov 12, 2024 | ▲ 850.3K |
SANDS CAPITAL MANAGEMENT, LLC biological products, (no diagnostic substances) | 1.42M | 2.53% | 2.53% | $211.18B | Nov 13, 2024 | ▼ 2.5K |
BANK OF NEW YORK MELLON CORP biological products, (no diagnostic substances) | 1.36M | 2.44% | 2.44% | $202.98B | Nov 12, 2024 | ▼ 6.4K |
MACQUARIE GROUP LTD biological products, (no diagnostic substances) | 1.20M | 2.15% | 2.15% | $179.23B | Nov 14, 2024 | ▼ 17.6K |
BROWN CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 1.12M | 2.00% | 2.00% | $166.62B | Nov 12, 2024 | ▼ 174.1K |
IMPAX ASSET MANAGEMENT GROUP PLC biological products, (no diagnostic substances) | 1.06M | 1.89% | 1.89% | $156.44B | Nov 6, 2024 | ▼ 68.7K |
Data from SEC Form 13F filings. Ownership bar normalised to largest holder. Change flags: isNew / isSoldOut / changeInSharesNumber (FMP extract-analytics/holder).
Institutional Activity
Q3 2024 vs prior quarter
Q3 2024
25
Increased
+4.59M shares1
New Positions
first time holders23
Decreased
−1.86M shares0
Sold Out
fully exitedNet shares change (top 50)
+2.73M
+4.59M / −1.86M
Net new holders
+3
1 new / 0 exited
Based on top 50 institutional holders by position size. Fields: isNew, isSoldOut, changeInSharesNumber (FMP extract-analytics/holder, limit=50).
Insider Buying vs Selling
RGEN insider trading · insider activity
Source: SEC Form 4
Insiders have been primarily selling shares recently. Selling may be driven by pre-scheduled Rule 10b5-1 plans rather than negative sentiment.
2
Buy transactions
2
Sell transactions
1.00
Buy/Sell ratio
$0M
Total disposed
Recent Insider Transactions
Showing 10 most recent · Common Stock only
| Name · Role | Date | Type | Shares | Price | Value | After Trans. | Filing |
|---|---|---|---|---|---|---|---|
Madaus Martin D director | May 14, 2026 | Award | 995 | — | — | 6.6K | Form 4 ↗ |
Madaus Martin D director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
Konstantinov Konstantin director | May 14, 2026 | Award | 995 | — | — | 3.9K | Form 4 ↗ |
Konstantinov Konstantin director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
EGLINTON MANNER CARRIE director | May 14, 2026 | Award | 995 | — | — | 5.5K | Form 4 ↗ |
Mhatre Rohin director | May 14, 2026 | Award | 995 | — | — | 5.0K | Form 4 ↗ |
Mhatre Rohin director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
EGLINTON MANNER CARRIE director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
Pax Margaret director | May 14, 2026 | Award | 995 | — | — | 3.0K | Form 4 ↗ |
Pax Margaret director | May 14, 2026 | Award | 2,239 | $103.38 | $231.5K | 2.2K | Form 4 ↗ |
Source: /insider-trading/search (FMP stable). Buy/Sell direction: acquisitionOrDisposition A=Buy, D=Sell. RSU vesting (M-Exempt) excluded from sentiment bar. All data from SEC EDGAR public filings.
About institutional & insider ownership
Repligen Corporation (RGEN) is primarily owned by institutional investors, who hold approximately 98.4% of total shares outstanding. Company insiders own approximately 5.40%, while retail and public investors account for the remaining 0.00%.
The largest institutional shareholder of Repligen Corporation is BLACKROCK, INC., holding approximately 7.11 million shares — equal to 12.69% of outstanding shares — as of September 30, 2024.
A total of 462 institutional investors currently hold RGEN stock, with a combined institutional value of approximately $8.25 billion as of the most recent 13F filing period.
Frequently asked questions
RGEN ownershipRepligen Corporation (RGEN) is primarily owned by institutional investors, who hold approximately 98.4% of shares. The largest shareholder is BLACKROCK, INC. with a 12.69% stake. Company insiders hold 5.40%. Data sourced from SEC Form 13F as of September 30, 2024.